- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00151866
Efficacy of Transfusions With Platelets Stored in Platelet Additive Solution II Versus Plasma
February 26, 2007 updated by: Sanquin Research & Blood Bank Divisions
A Multicentre Randomised Study of the Efficacy of Transfusions With Platelets Stored in Platelet Additive Solution II Versus Plasma
The purpose of this study is to evaluate the clinical efficacy of transfusions with platelets stored in platelet additive solution II compared to plasma storage.
Study Overview
Status
Completed
Intervention / Treatment
Detailed Description
Introduction: Utilization of platelet additive solutions (PASs) for storage of platelets has several advantages, however randomised studies testing the clinical efficacy are scarce.
A prospective, randomised study comparing the efficacy of transfusions with platelets stored in Platelet Additive Solution II (PAS II) versus plasma showed that CCIs after transfusion with platelets stored in PAS II were significantly lower (1).
Major drawbacks of this study were the exclusion of patients with clinical factors known to increase platelet consumption and a limited number of patients.
A multicenter, randomised study to investigate clinical efficacy of platelets stored in PAS II versus plasma, also including patients with factors of increased platelet consumption, was performed.
Methods: After consent patients > 18 years, without HLA- and/or HPA-alloantibodies, were randomised to receive pooled platelet concentrates (PC) suspended in either plasma or PAS II, leucoreduced, and stored up to 5 days.
1- and 24-hour CCI were the primary endpoints.
Secondary endpoints were transfusion interval, adverse reactions and bleeding complications.
An inclusion-period was defined as a maximum of 8 transfusions or 30 days after the first transfusion.
Study Type
Interventional
Enrollment
180
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Leiden, Netherlands
- Leiden University Medical Centre
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:patients > 18 years expected to receive platelet transfusions and informed consent -
Exclusion Criteria:HLA- and/or HPA- alloimmunization
-
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: Double
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
Corrected count increment
|
Secondary Outcome Measures
Outcome Measure |
---|
Bleeding complications
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: J.L.H. Kerkhoffs, MD, Sanquin rbbd
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
October 1, 2003
Study Completion
May 1, 2005
Study Registration Dates
First Submitted
September 7, 2005
First Submitted That Met QC Criteria
September 7, 2005
First Posted (Estimate)
September 9, 2005
Study Record Updates
Last Update Posted (Estimate)
February 27, 2007
Last Update Submitted That Met QC Criteria
February 26, 2007
Last Verified
September 1, 2005
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- P03.113
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Thrombocytopenia
-
Weill Medical College of Cornell UniversityColumbia University; New York Presbyterian HospitalCompletedAlloimmune Thrombocytopenia | Fetal Alloimmune ThrombocytopeniaUnited States
-
Sylvia ElzekUnknownThrombocytopenia Neonatal
-
Central Hospital, Nancy, FranceRecruitingHeparin-induced ThrombocytopeniaFrance
-
Centre Hospitalier Universitaire de BesanconNot yet recruitingHeparin-induced Thrombocytopenia
-
University of ArizonaAmerican College of Clinical PharmacyRecruitingHeparin-induced ThrombocytopeniaUnited States
-
Veralox TherapeuticsCelerionCompletedHeparin-induced ThrombocytopeniaUnited States
-
Aspen Global IncorporatedTerminatedHeparin-induced ThrombocytopeniaUnited States, Bosnia and Herzegovina, Canada, France, Germany, Italy, Poland, Russian Federation, Serbia
-
Marshall UniversityUnknownHeparin-induced ThrombocytopeniaUnited States
-
Ottawa Hospital Research InstituteUnknownHeparin-induced Thrombocytopenia (HIT)Canada
-
Assistance Publique Hopitaux De MarseilleWithdrawnNeonatal Thrombocytopenia Isoimmunization Maternal-fetalFrance
Clinical Trials on platelet transfusion
-
National Institutes of Health Clinical Center (CC)Recruiting
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)TerminatedAcute Myeloid Leukemia | Primary Myelofibrosis | Thrombocytopenia | Acute Lymphoblastic Leukemia | Chronic Lymphocytic Leukemia | Venous Thromboembolism | Myelodysplastic Syndrome | B-Cell Non-Hodgkin Lymphoma | Hematopoietic Cell Transplantation Recipient | Chronic Myelogenous Leukemia, BCR-ABL1 Positive and other conditionsUnited States
-
University of OklahomaCompletedThrombocytopeniaUnited States
-
Technische Universität DresdenCompletedMyeloid LeukemiaGermany
-
University Hospital TuebingenWithdrawnSepsis | Thrombocytopenia
-
Sofia RamströmEnrolling by invitation
-
Prophylix Pharma ASLarix A/S; Fraunhofer Institute for Molecular Biology and Applied Ecology; Deutsches... and other collaboratorsCompletedFetal and Neonatal Alloimmune ThrombocytopeniaGermany
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedHematologic Diseases | Blood Transfusion | Leukemia, Myelocytic, Acute | Immunization | Blood Platelets
-
Ottawa Hospital Research InstituteCanadian Institutes of Health Research (CIHR); Canadian Blood ServicesTerminatedLeukemia | Myelodysplastic SyndromeCanada
-
M.D. Anderson Cancer CenterTerminatedLymphoma | LeukemiaUnited States